Biogen (BIIB) traded lower on Wednesday after HSBC downgraded the company from Hold to Reduce, handing the Alzheimer’s drug ...

Six companies, including Alnylam Pharmaceuticals (ALNY) and Seagate Technology Holdings (STX), are set to join the Nasdaq 100 ...

If you have been wondering whether Biogen's recent share price makes it a bargain or a value trap, you are not alone. This article is designed to help you cut through the noise and focus on what the ...

Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...

Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift ...

Biogen is showing CEO Michel Vountasos to the door in the aftermath of its Aduhelm debacle. As the company searches for a new leader, one skill set stands out to investors as the most-coveted piece of ...

Biogen has formed a research collaboration with privately held Dayra Therapeutics to discover and develop oral macrocyclic peptides for targets in immunological conditions. Biogen on Monday said it ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen could help children with spinal muscular atrophy (SMA) who are still ...

For years, federal prosecutors have gone after drug companies for allegedly using charity contributions as a way to boost sales. Biogen was among the pharma players to ink a federal settlement, but ...

Biogen is planning to file for FDA approval of its failed Alzheimer’s disease drug aducanumab. The drug flunked a futility analysis in March, but Biogen resurrected it after factoring in data ...

Biogen announced it will buy Human Immunology Biosciences (HI-Bio) in a deal worth up to $1.8 billion Wednesday morning. Per terms of the transaction, Biogen will make an upfront payment of $1.15 ...

The downfall of Aduhelm, the first new treatment for Alzheimer’s disease in two decades, is largely the story of a drug company choosing to maximize its potential profits at the expense of patients ...